hepatic encephalopathy
Information
- Disease name
- hepatic encephalopathy
- Disease ID
- DOID:13413
- Description
- "A brain disease that is characterized by loss of brain function, the occurrence of confusion, altered level of consciousness, and coma that results when the liver is unable to remove toxins from the blood." [url:https\://en.wikipedia.org/wiki/Hepatic_encephalopathy]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05669651 | Active, not recruiting | N/A | Explore the Efficacy and Safety of FMT With Different Bacterial Doses in the Treatment of Hepatic Encephalopathy | December 1, 2022 | December 31, 2025 |
| NCT03420482 | Active, not recruiting | Phase 2 | Fecal Microbiota Transplant as Treatment of Hepatic Encephalopathy | April 1, 2018 | January 31, 2024 |
| NCT05071716 | Active, not recruiting | Phase 3 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | April 7, 2022 | September 2025 |
| NCT05425316 | Active, not recruiting | Speech in Hepatic Encephalopathy (HE) | October 5, 2021 | August 2024 | |
| NCT05297448 | Active, not recruiting | Phase 3 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | August 3, 2022 | January 2026 |
| NCT00305591 | Completed | N/A | Brain Imaging in Patients With Chronic Liver Disease and Functional Impairment. | March 2006 | October 2007 |
| NCT00375375 | Completed | Phase 4 | Effect of Lactulose on Minimal Hepatic Encephalopathy and Health-Related Quality of Life | January 2004 | December 2004 |
| NCT00424957 | Completed | Brain Energy Metabolism in Patients With Chronic Liver Disease and Impaired Central Nervous System | November 2006 | October 2008 | |
| NCT00433368 | Completed | Phase 3 | Efficacy of L-Ornithine-L-Aspartate in Cirrhotics With Hepatic Encephalopathy | October 2003 | September 2004 |
| NCT00533910 | Completed | N/A | Rifaximin in Minimal Hepatic Encephalopathy | October 2007 | May 2010 |
| NCT00558038 | Completed | Phase 2 | Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy | September 2007 | June 2009 |
| NCT00655304 | Completed | N/A | The Effect of Prometheus (R) Liver Support Dialysis on Cerebral Metabolism in Acute Liver Failure | March 2007 | June 2011 |
| NCT00686920 | Completed | Phase 3 | Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy | March 7, 2007 | December 8, 2010 |
| NCT00740142 | Completed | Phase 4 | Efficacy of Combined Oral L-ornithine-L-aspartate and Lactulose in Patients With Hepatic Encephalopathy | September 2008 | October 2011 |
| NCT00839358 | Completed | Phase 4 | Effect of Midodrine and Albumine in the Prevention of Complications in Cirrhotic Patients Awaiting Liver Transplantation | August 2008 | February 2016 |
| NCT00886925 | Completed | Phase 4 | Efficacy of Albumin for Acute Encephalopathy in Patients With Cirrhosis | March 2009 | July 2012 |
| NCT05526404 | Completed | N/A | Prevention of Hepatic Encephalopathy With Mobile Application Based Lactulose Titration | September 14, 2022 | July 8, 2023 |
| NCT00914056 | Completed | N/A | A Study of Controlled Lactulose Withdrawal | September 2008 | May 2012 |
| NCT00931060 | Completed | N/A | Effects of Branched-Chain Amino Acids on Muscle Ammonia Metabolism in Patients With Cirrhosis and Healthy Subjects | November 2007 | June 2009 |
| NCT00955500 | Completed | Phase 4 | Effects of Proteins in Patients With Cirrhosis and Prior Hepatic Encephalopathy | January 2003 | January 2009 |
| NCT00986648 | Completed | A Multi-Center Group to Study Acute Liver Failure in Children | January 2000 | December 2015 | |
| NCT00986895 | Completed | Phase 1 | A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group | September 2006 | June 2007 |
| NCT00999167 | Completed | Phase 2 | A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy | December 2009 | April 2012 |
| NCT01008293 | Completed | Phase 2/Phase 3 | Effect of Probiotics in Treatment of Minimal Hepatic Encephalopathy (MHE) and Health Related Quality of Life | October 2009 | October 2012 |
| NCT01041755 | Completed | Phase 4 | Efficacy of L-Ornithine L-Aspartate in Acute Hepatic Encephalopathy. | November 2009 | June 2011 |
| NCT01059396 | Completed | Phase 4 | Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal | January 28, 2010 | July 15, 2015 |
| NCT01099293 | Completed | Cerebrovascular Reactivity in Hepatic Encephalopathy | March 2010 | September 2011 | |
| NCT01110447 | Completed | Phase 2/Phase 3 | Secondary Prophylaxis of Hepatic Encephalopathy With a Probiotic Preparation | April 2010 | March 2013 |
| NCT05376488 | Completed | N/A | Effect of Brief Dietary Intervention on Ammonia Levels | May 1, 2022 | April 20, 2023 |
| NCT01151475 | Completed | Cerebral Oxygen, Blood Flow and Ammonia Uptake in Patients With Cirrhosis and an Acute Episode of Hepatic Encephalopathy (HE) | August 2010 | August 2011 | |
| NCT02488993 | Completed | Real World Outcomes Study of Hepatic Encephalopathy Patients' Experience on Rifaximin (PROSPER) | June 2015 | September 29, 2018 | |
| NCT00248625 | Completed | Phase 3 | N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure | January 2000 | October 2010 |
| NCT00004796 | Completed | Phase 2 | Phase II Study of Lactulose and Circadian Rhythms in Patients With Cirrhosis | November 1994 | February 1997 |
| NCT00287235 | Completed | N/A | Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS) | September 2000 | April 2004 |
| NCT00298038 | Completed | Phase 3 | A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy | December 19, 2005 | August 15, 2008 |
| NCT02636647 | Completed | Phase 1 | Fecal Transplant in Recurrent Hepatic Encephalopathy | October 2015 | August 2016 |
| NCT02613858 | Completed | Minimal HePatic Encephalopathy Among CiRrhotics. A Cross SEctional, Clinico-EpidEmiological, Multi-Centre, Study in Patients of PakisTan | November 2015 | May 2017 | |
| NCT01218568 | Completed | N/A | Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial | October 2010 | October 2012 |
| NCT01223742 | Completed | N/A | Oral Acetyl-L-Carnitine Therapy Reduces Fatigue In Hepatic Encephalopathy | June 2002 | December 2006 |
| NCT01283152 | Completed | N/A | Efficacy Study of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) Versus Lactulose in Patients With Hepatic Encephalopathy. | January 2011 | June 2012 |
| NCT05033327 | Completed | N/A | Feasibility of an App-based Nutrition & Exercise Program in Cirrhosis | April 20, 2021 | December 31, 2022 |
| NCT04899115 | Completed | Phase 2 | VE303 for Treatment of Hepatic Encephalopathy (HE) | August 6, 2021 | August 30, 2023 |
| NCT01446523 | Completed | N/A | S. Endotoxin, Inflammatory Mediators and MRS Before and After Treatment in MHE | October 2011 | February 2012 |
| NCT01494064 | Completed | Monitoring of Encephalopathy in Cirrhotic Patients Admitted in Intensive Care | February 2011 | December 2015 | |
| NCT01556646 | Completed | Phase 3 | Effect of Tolvaptan on Cognitive Function in Cirrhosis | April 2011 | June 2013 |
| NCT01559519 | Completed | Phase 4 | Post Transjugular Intrahepatic Portosystemic Shunt (Tips) Albumine Infusion to Prevent Hepatic Encephalopathy | September 2012 | December 2013 |
| NCT01603953 | Completed | Bioelectrical Impedance Vector Analysis in Cirrhotic Patients | January 2009 | May 2014 | |
| NCT01722578 | Completed | Phase 4 | L-ornithine L-aspartate in Overt Hepatic Encephalopathy | December 2013 | January 2017 |
| NCT01773538 | Completed | N/A | Diagnosis of Covert/Minimal Hepatic Encephalopathy by Means of Continuous Reaction Time Measurement | January 2013 | November 2015 |
| NCT04787276 | Completed | N/A | Efficacy and Safety of E.Coli Nissle 1917 in Patients With Mild (Stage 1-2) or Minimal Hepatic Encephalopathy | January 10, 2017 | March 15, 2020 |
| NCT04771104 | Completed | N/A | The Effect of Induced Hyperammonaemia on Sleep and Melanopsin-mediated Pupillary Light Response in Patients With Liver Cirrhosis | January 1, 2017 | January 22, 2018 |
| NCT04736836 | Completed | Phase 4 | Microbial Resistance of Rifaximin in Hepatic Encephalopathy | January 2015 | June 2019 |
| NCT01842581 | Completed | Phase 4 | The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy | January 8, 2013 | December 17, 2014 |
| NCT04698148 | Completed | Establishment of the Human Intestinal and Salivary Microbiota Biobank - Gastrointestinal Diseases | February 8, 2021 | May 10, 2022 | |
| NCT04675775 | Completed | N/A | The BRAINFOOD Trial to Prevent Recurrent Hepatic Encephalopathy. | January 21, 2021 | March 5, 2023 |
| NCT04238416 | Completed | Phase 1 | Intravenous Branched Chain Amino Acids for Hepatic Encephalopathy in ACLF | November 1, 2019 | December 30, 2021 |
| NCT01847651 | Completed | Phase 4 | Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate | August 2013 | June 2015 |
| NCT01878305 | Completed | Neuromonitoring of Hepatic Encephalopathy | December 2005 | December 2011 | |
| NCT04082780 | Completed | Phase 2 | Rifamycin in Minimal Hepatic Encephalopathy | September 1, 2019 | April 28, 2023 |
| NCT04058327 | Completed | A Study of MHE in Patients With Liver Diseases | May 1, 2019 | December 30, 2022 | |
| NCT01966419 | Completed | Phase 2 | Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE) | January 7, 2014 | December 29, 2016 |
| NCT02017119 | Completed | Phase 2 | Comparison Between Lactulose and Lactulose-Paraffin in Cirrhotic Patients | January 2011 | June 2014 |
| NCT03796598 | Completed | Phase 1/Phase 2 | FMT in Cirrhosis and Hepatic Encephalopathy | July 29, 2019 | December 20, 2023 |
| NCT03586115 | Completed | Minimal Hepatic Encephalopathy in Hereditary Hemorrhagic Telangiectasian | January 8, 2018 | April 30, 2020 | |
| NCT02083367 | Completed | Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome | January 2013 | February 2015 | |
| NCT03585257 | Completed | Phase 2 | HEAL STUDY (Hepatic Encephalopathy and Albumin Study) | June 20, 2018 | March 30, 2022 |
| NCT02154282 | Completed | N/A | iPod Games in Hepatic Encephalopathy | January 2013 | July 2016 |
| NCT02158182 | Completed | Phase 4 | Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding | July 2014 | June 2016 |
| NCT02163837 | Completed | N/A | Effect of Rifaximine on Sleep Disorders in Patients Suffering From Hepatic Encephalopathy | March 2014 | July 2015 |
| NCT03493204 | Completed | N/A | Tackling 30-day Readmissions in Patients With Cirrhosis: The SALTYFOOD Trial | April 24, 2018 | August 19, 2019 |
| NCT02255617 | Completed | Phase 1/Phase 2 | Fecal Microbiota Transplantation (FMT) in the Management of Hepatic Encephalopathy (HE): a Pilot Study | July 23, 2014 | September 23, 2019 |
| NCT03439982 | Completed | Phase 1/Phase 2 | Fecal Transplant for Hepatic Encephalopathy | April 12, 2016 | March 18, 2021 |
| NCT02377947 | Completed | A Retrospective, Open-label, Uncontrolled Cohort Study to Assess the Effectiveness and Safety of Lactulose Retention Enema in the Treatment of Cirrhotic Patients With Grade 3 or 4 (West Haven Criteria) Hepatic Encephalopathy (HE) [The RETRO Study] | December 2015 | March 2016 | |
| NCT03152188 | Completed | Phase 1 | Oral Fecal Transplant in Cirrhosis | June 12, 2017 | November 12, 2018 |
| NCT05433948 | Enrolling by invitation | Diagnosing Minimal Hepatic Encephalopathy | December 1, 2019 | December 1, 2031 | |
| NCT06367127 | Enrolling by invitation | Utility of the Clamping Bean Test (CBT) for Covert Hepatic Encephalopathy Screening | October 9, 2023 | December 31, 2024 | |
| NCT06425380 | Not yet recruiting | Phase 2 | Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy | June 2024 | April 2026 |
| NCT05772585 | Not yet recruiting | Characterization of Metabolomic Fingerprints in Patients With Acute Liver Failure and Acute-on-chronic Liver Failure With Hepatic Encephalopathy | March 2023 | October 2023 | |
| NCT05788627 | Not yet recruiting | Phase 4 | Effectiveness of Oral Lactulose Versus Lactulose Enema in Hepatic Encephalopathy | April 2023 | November 2023 |
| NCT06072521 | Not yet recruiting | Phase 2 | Efficacy of Lactoferrin as an Adjunct Therapy in Patients With Hepatic Encephalopathy | October 2023 | October 2024 |
| NCT06075875 | Not yet recruiting | N/A | Vegetable Proteins Versus Mixed Animal Proteins on the Outcome of Hepatic Encephalopathy | December 23, 2023 | January 2025 |
| NCT06201988 | Not yet recruiting | Revealing Engagement Patterns Among Hepatic Encephalopathy Patients | January 2025 | January 2027 | |
| NCT05206487 | Recruiting | N/A | Hepatic Encephalopathy Prevention With Polydextrose After TIPS: Pilot Study (POEME) | May 9, 2022 | June 30, 2025 |
| NCT03267615 | Recruiting | VICIS - Vienna Cirrhosis Study | February 1, 2017 | December 31, 2027 | |
| NCT06052176 | Recruiting | Phase 2 | Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement | November 2, 2023 | June 1, 2025 |
| NCT06040814 | Recruiting | N/A | Microbiota, Sarcopenia, and Hepatic Encephalopathy Change in Cirrhotic Patients Before and After Rehabilitation | December 1, 2022 | November 30, 2025 |
| NCT05140837 | Recruiting | Early Diagnosis and Timely Treatment of Cirrhotic Patients With Minimal Hepatic Encephalopathy (CHESS-NCRCID 2106) | December 9, 2021 | December 31, 2024 | |
| NCT05070351 | Recruiting | Phase 1/Phase 2 | Deprescribing Proton Pump Inhibitors to Reduce Post-TIPS Hepatic Encephalopathy | January 3, 2022 | October 2028 |
| NCT06328088 | Recruiting | Vegetarian Versus Non Vegetarian Based Diet in the Recurrence of Hepatic Encephalopathy in Patients With Cirrhosis: An Open Label Pilot Study | February 16, 2024 | October 16, 2024 | |
| NCT04862221 | Recruiting | Phase 2 | TReatment for ImmUne Mediated PathopHysiology | February 9, 2022 | January 31, 2027 |
| NCT06245473 | Recruiting | Metobolomics in the Characterisation of HE | April 23, 2024 | April 23, 2024 | |
| NCT05786859 | Recruiting | Early Phase 1 | The Efficacy and Safety of Rifaximin Treatment | March 9, 2023 | October 31, 2025 |
| NCT06248736 | Recruiting | Description of Lactulose Administration by Balloon Rectal Tube in Severe Hepatic Encephalopathy | June 7, 2022 | December 31, 2024 | |
| NCT05754996 | Recruiting | Phase 3 | Comparing Nifuroxazide Plus Lactulose With Lactulose Alone in the Treatment of Hepatic Encephalopathy | March 12, 2023 | December 2024 |
| NCT04014413 | Recruiting | N/A | Safety and Efficacy of Fecal Microbiota Transplantation | July 15, 2019 | October 31, 2030 |
| NCT05700695 | Recruiting | Phase 1 | Intravenous BCAA for HE in ACLF (BCAA-HE-ACLF) | January 17, 2023 | April 25, 2025 |
| NCT05566548 | Recruiting | Role of Bilirubin Molecular Species in Hepatic Encephalopathy and Acute-on-chronic Liver Failure | August 1, 2022 | August 1, 2023 | |
| NCT05539027 | Recruiting | Phase 4 | Efficacy of L-Ornithine L-Aspartate (LOLA) as an Adjunct to Branched Chain Amino Acids (BCAA) Enriched Solutions on Clinical Outcomes in ICU Patients With Hepatic Encephalopathy | September 20, 2022 | July 15, 2024 |
| NCT04096014 | Recruiting | N/A | Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy | September 16, 2019 | October 30, 2026 |
| NCT05511766 | Recruiting | Phase 2/Phase 3 | Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis | November 15, 2022 | January 30, 2025 |
| NCT05466669 | Recruiting | Prediction of Post-TIPS Hepatic Encephalopathy in Patients With Liver Cirrhosis | March 9, 2022 | February 10, 2025 | |
| NCT06179368 | Recruiting | Throid Dysfunction in Liver Failure and Its Eddects Upon Outcome | January 1, 2024 | May 1, 2024 | |
| NCT04161053 | Recruiting | Phase 3 | Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy | November 1, 2018 | December 2028 |
| NCT06368895 | Recruiting | Phase 1 | Fecal Microbiota Transplantation by Oral Capsules for Hepatic Encephalopathy Treatment | April 7, 2021 | June 2025 |
| NCT05421351 | Recruiting | Immune Profile, Neuronal Dysfunction, Metabolomics and Ammonia in Therapeutic Response of HE in ACLF | October 2, 2022 | May 2025 | |
| NCT05346029 | Recruiting | N/A | Role of Sarcopenia and Nutritional/Physical Therapy Intervention in Post-TIPS Hepatic Encephalopathy | January 1, 2022 | December 31, 2025 |
| NCT04436601 | Recruiting | Phase 4 | Polyethylene Glycol Versus Lactulose on Hepatic Encephalopathy in Patients With Cirrhosis;(PEGHE Trial) | March 9, 2020 | December 30, 2023 |
| NCT00364689 | Terminated | Phase 3 | RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial | August 2006 | July 2008 |
| NCT02026609 | Terminated | Glutamine Challenge as Predictor of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS) | May 2013 | January 27, 2015 | |
| NCT04155099 | Terminated | Phase 2 | Investigational Microbiota Restoration Therapeutic for Hepatic Encephalopathy | March 1, 2021 | July 30, 2023 |
| NCT01846819 | Terminated | Factors Associated With End Stage Liver Disease | July 2012 | December 2014 | |
| NCT01846806 | Terminated | N/A | The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy. | September 2012 | March 2016 |
| NCT01846663 | Terminated | Phase 4 | Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy | April 3, 2013 | February 22, 2016 |
| NCT01842113 | Terminated | Phase 4 | Quality of Life and Nutritional Improvements in Cirrhotic Patients | April 2013 | |
| NCT04816916 | Terminated | Phase 2 | Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy | June 29, 2021 | June 30, 2022 |
| NCT04940416 | Terminated | Eye Movement Testing for Diagnosing Encephalopathy in Patients With Liver Disease | August 31, 2017 | June 17, 2021 | |
| NCT01113567 | Terminated | N/A | Effect of Lactose in Patients With Chronic Liver Disease and Minimal Hepatic Encephalopathy | July 2010 | July 26, 2021 |
| NCT00985010 | Terminated | Manganese in Women With Encephalopathy | January 2003 | January 2005 | |
| NCT00597909 | Terminated | Phase 2 | Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy | December 2007 | September 2008 |
| NCT01178372 | Unknown status | Phase 4 | Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis | September 2008 | September 2010 |
| NCT05128305 | Unknown status | Phase 3 | Integrated Traditional Chinese and Clinical Medicine for Chronic Hepatitis B and Its Complication | December 1, 2021 | December 30, 2022 |
| NCT01798329 | Unknown status | Phase 3 | ETOS: Minimal Hepatic Encephalopathy in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study | March 2013 | September 2015 |
| NCT03372499 | Unknown status | N/A | Diet Management on Hepatic Encephalopathy of Patients With Variceal Bleeding After Intrahepatic Portosystemic Shunt Creation | October 1, 2017 | December 2018 |
| NCT00281502 | Unknown status | Phase 2 | The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy | December 2005 | December 2012 |
| NCT03306498 | Unknown status | Plasma Free Amino Acids in Patients With Hepatic Encephalopathy | December 15, 2017 | February 15, 2019 | |
| NCT02470546 | Unknown status | Phase 4 | Metformin Experience on Minimal Hepatic Encephalopathy | March 2015 | December 2016 |
| NCT01434056 | Unknown status | Prediction of Mortality in Patients Waiting for Liver Transplantation Through Brain Magnetic Resonance Imaging | November 2011 | February 2015 | |
| NCT02692430 | Unknown status | The International Imaging Registry in Liver Cirrhosis (BAVENO-VI SPSS GROUP). | April 2016 | December 2017 | |
| NCT01356121 | Unknown status | Phase 4 | Trial Comparing Sedation for Endoscopy With Propofol Versus Midazolam in Cirrhotics | November 2010 | July 2011 |
| NCT05229289 | Unknown status | N/A | Efficacy and Safety of Fecal Microbiota Transplant for Secondary Prophylaxis of Hepatic Encephalopathy | January 31, 2022 | December 31, 2022 |
| NCT05279586 | Unknown status | Early Phase 1 | Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhotic Patients | March 2022 | March 2023 |
| NCT01175538 | Unknown status | Phase 4 | Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis | January 2008 | September 2010 |
| NCT04415294 | Unknown status | Flicker App for Minimal Hepatic Encephalopathy | October 22, 2019 | June 30, 2023 | |
| NCT02858778 | Unknown status | N/A | Timing of Acute Palliative Care Consultation in Critically Ill Patients | June 2016 | |
| NCT04317222 | Unknown status | N/A | Early Postoperative CRRT After Liver Transplantation in ACLF Patients With Overt HE | June 1, 2020 | August 31, 2022 |
| NCT01097811 | Unknown status | N/A | Comparison Between Erythromycin and Neomycin Treatment of Hepatic Encephalopathy | June 2008 | December 2010 |
| NCT03100513 | Unknown status | Phase 4 | PEG (Polyethylene Glycol)Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy | March 11, 2017 | December 2019 |
| NCT04131205 | Unknown status | Role of MRI in Detection of Minimal Hepatic Encephalopathy | June 1, 2019 | June 1, 2023 | |
| NCT00896831 | Unknown status | Phase 4 | Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy | November 2008 | September 2010 |
| NCT04073290 | Unknown status | Phase 4 | Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose | January 21, 2020 | September 30, 2023 |
| NCT02427906 | Unknown status | Effect of Transjugular Intrahepatic Portosystemic Shunt on Gut Microbiota in Cirrhotic Patients | August 2014 | April 2016 | |
| NCT03987893 | Unknown status | Phase 4 | PEG3350 in ACLF With Hepatic Encephalopathy | May 20, 2018 | August 20, 2020 |
| NCT03961087 | Unknown status | N/A | Coenzyme Q10 and Meclofenoxate in Hepatic Encephalopathy | May 23, 2019 | February 1, 2020 |
| NCT03825848 | Unknown status | N/A | The Influence of Post-transjugular Intrahepatic Portosystemic Shunt Hepatic Encephalopathy | June 20, 2019 | December 31, 2023 |
| NCT02177708 | Unknown status | Quantitative Determination of Brain Water Content in Patients During and After Hepatic Encepalopathy | January 2014 | December 2015 | |
| NCT02334163 | Unknown status | Phase 2 | The Effects of Nitazoxanide in Hepatic Encephalopathy | December 2014 | April 2015 |
| NCT02401490 | Unknown status | Phase 4 | Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy | April 2015 | March 2018 |
| NCT04664621 | Withdrawn | N/A | HepQuant to Predict Hepatic Encephalopathy After TIPS | February 25, 2020 | September 30, 2021 |
| NCT02086825 | Withdrawn | Phase 3 | A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure | October 2015 | |
| NCT01777971 | Withdrawn | The Effect of a Large-volume Paracentesis on Fatigue, Sleep, and Quality of Life in Cirrhosis | July 2012 | October 2014 | |
| NCT01923376 | Withdrawn | N/A | Hepatic Encephalopathy: Lactulose or Polyethylene Glycol (H.E.L.P.) | February 2013 | February 2014 |
| NCT04128462 | Withdrawn | Phase 3 | MNK-6105 for Patients With Cirrhosis and High Ammonia Levels Affecting Brain Function | November 2021 | July 2025 |
| NCT02048969 | Withdrawn | Phase 1/Phase 2 | Treatment of Hepatic Encephalopathy With Flumazenil and Change in Cortical GABA Levels in MRS | June 2014 | October 2017 |
| NCT01882855 | Withdrawn | Effect of Music on Attention and Prospective Memory in Hepatic Encephalopathy | December 2012 | March 2016 |
- Disase is a (Disease Ontology)
- DOID:936
- Cross Reference ID (Disease Ontology)
- GARD:10452
- Cross Reference ID (Disease Ontology)
- ICD10CM:K76.82
- Cross Reference ID (Disease Ontology)
- ICD9CM:572.2
- Cross Reference ID (Disease Ontology)
- MESH:D006501
- Cross Reference ID (Disease Ontology)
- NCI:C79596
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:197332007
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0019151
- Exact Synonym (Disease Ontology)
- Portal-systemic encephalopathy
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0002480
- MeSH unique ID (MeSH (Medical Subject Headings))
- D006501